Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption

PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

August 31, 2014

Study Completion Date

September 30, 2015

Conditions
HIV Infection
Interventions
BIOLOGICAL

AGS-004

HIV-1 Immune Therapy

BIOLOGICAL

Placebo

Inactive Placebo Injection

Trial Locations (9)

10461

Jacobi & North Central Bronx Hospitals, The Bronx

27514

AIDS Clinical Trials Unit, Chapel Hill

27710

Duke University Medical Center, Durham

95811

UCDavis Research Office at CARES, Sacramento

191002

Division of Infectious Disease and HIV Medicine Partnership Comprehensive Care Practice, Philadelphia

K1H 816

The Ottawa Hospital, Ottawa

H2L4P9

Clinique médicale l'Actuel, Montreal

H2L5B1

Clinique Médical du Quartier Latin, Montreal

H2X 2P4

Montreal Chest Institute, Immunodeficiency Dept., Montreal

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Argos Therapeutics

INDUSTRY

NCT01069809 - Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption | Biotech Hunter | Biotech Hunter